16: Peptalk Deep Dive — KPV Airs Monday, November 16, 2026
From PEPtalk · 12:32
Show by Jake & Cynthia
Three amino acids with an outsized reputation. KPV — lysine, proline, valine — is the last three residues of alpha-MSH, the smallest peptide we've covered, with some of the most consistent gut inflammation data in mice and zero human trials. We unpack what it is, how it works through the PepT1 transporter instead of melanocortin receptors, what the colitis studies actually show, and why the regulatory door has opened a crack.GLP pulse: your genes may decide how well semaglutide works (Nature Metabolism, November 11); lower-dose CagriSema posted ~21% weight loss at ObesityWeek (REDEFINE 9) and early responders averaged 25.4% (REDEFINE 1 post-hoc); and a CDC report finds 44% of GLP-1 users changed how they took their medication, most often by skipping doses.Next Monday: the KLOW blend vs the GLOW blend, side by side — what does adding KPV buy you?Everything we discuss on this show is for research and informational purposes only. Not medical advice. We're describing the science, not recommending anything.Sources:• Levy et al., Nature Metabolism, November 11, 2026 — rare GLP1R variants and semaglutide vs tirzepatide response: https://www.nature.com/articles/s42255-026-01656-z• Novo Nordisk, REDEFINE 9 primary results (ObesityWeek, November 14, 2026) and REDEFINE 1 post-hoc analyses (November 15, 2026): https://www.prnewswire.com/news-releases/novos-cagrisema-was-associated-with-25-mean-weight-loss-among-early-responders-in-a-post-hoc-analysis-of-redefine-1-presented-at-obesityweek-2026-302939681.html• CDC, MMWR, November 12, 2026 — Use of GLP-1 Medications and Modified Medication Use Among Adults, United States, 2025: https://www.cdc.gov/mmwr/volumes/75/wr/mm7544a1.htm?s_cid=OS_mm7544a1_w• Hiltz ME, Lipton JM. Anti-inflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB Journal, 1989: https://pubmed.ncbi.nlm.nih.gov/2550304/• Dalmasso G, et al. The PepT1 transporter mediates KPV uptake and reduces intestinal inflammation in colitis models. Gastroenterology, 2008: https://pubmed.ncbi.nlm.nih.gov/18061177/• Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 2008: https://pubmed.ncbi.nlm.nih.gov/18092346/• Xiao B, et al. Hyaluronic acid-functionalized KPV nanoparticles in ulcerative colitis. Molecular Therapy, 2017: https://pubmed.ncbi.nlm.nih.gov/28143741/• Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides. Endocrine Reviews, 2008: https://pubmed.ncbi.nlm.nih.gov/18612139/• FDA Pharmacy Compounding Advisory Committee, July 23, 2026 — KPV recommended for the 503A bulks list (8-6, one abstention).• HHS interim enforcement policy, October 28, 2026 — single-ingredient KPV acetate (topical/oral) compoundingA Spoke-Media production:https://www.spoke-media.com
More episodes
- Peptalk Week in Review — November 13, 2026
- 14: Peptalk Deep Dive — GHK-Cu
- 13: Peptalk Week in Review — November 6, 2026
- 12: Peptalk Deep Dive — Wolverine stack
- 11: Peptalk Week in Review — October 30, 2026
- 10: Peptalk Deep Dive - TB-500
- 9: Peptalk Week in Review — October 23, 2026
- 8: Bonus Episode: “Peptides” explained
- 7: Peptalk Deep Dive — BPC-157
- 6: Peptalk Week in Review — October 16, 2026
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.